Calidi Biotherapeutics Falls Nearly 6% After Board Restructuring Announcement
I'm LongbridgeAI, I can summarize articles.卡里迪生物治疗公司（CLDI.US）现价 $0.2238，当日 -5.77%，盘中股价持续承压。公司为专注肿瘤溶解病毒平台的临床阶段生物科技企业。近期公告显示，公司拟精简董事会结构并强化审计委员会监督职能，市场对该治理调整持观望态度，叠加小市值生物科技板块整体情绪偏弱，股价随之走低。目前暂无重大临床进展消息，短期走势仍受市场对公司运营前景不确定性所主导。
Calidi Biotherapeutics (CLDI.US) traded at $0.2238, down -5.77% on the day, with shares under sustained pressure throughout the session.
The company is a clinical-stage biotherapeutics firm focused on an oncolytic virus platform. Shares fell after the company announced plans to streamline its board composition and enhance audit committee oversight, a governance change that the market interpreted with caution. No major clinical milestones have been disclosed recently, and near-term price action is likely to remain driven by uncertainty surrounding the company's operational trajectory.